Showing 2091-2100 of 5771 results for "".
- Tarsus Pharmaceuticals Announces Appointment of New COO and CFOhttps://modernod.com/news/tarsus-pharmaceuticals-announces-appointment-of-new-coo-and-cfo/2478029/Tarsus Pharmaceuticals announced the appointment of two pharmaceutical veterans to its executive leadership team: Sesha Neervannan, PhD, to the position of Chief Operating Officer (COO), and Leo Greenstein to the position of Chief Financial Officer (CFO). As part of its leadership, Sesha and Leo
- Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Insertshttps://modernod.com/news/ocular-therapeutix-announces-its-first-published-physician-fee-schedule-for-administration-of-intracanalicular-inserts/2478025/Ocular Therapeutix announced that Novitas Solutions, one of seven Medicare Administrative Contractors (MACs), became the first MAC to establish a physician fee schedule for procedure code 0356T for the administration of drug-elutin
- Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strengthhttps://modernod.com/news/alcon-announces-fda-approval-of-the-otc-switch-of-pataday-once-daily-relief-extra-strength/2478016/Alcon announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, has been approved by the FDA for sale over-the-counter (OTC) in the United States. Pataday Once Daily Relief Extra Strength is the first and only once
- Sensible Medical Announces Partnership Aimed at Restoring Confidence for Safe Surgery During COVID-19https://modernod.com/news/sensible-medical-announces-partnership-aimed-at-restoring-confidence-for-safe-surgery-during-covid-19/2478015/Sensible Medical has announced exclusive distribution rights for the United States and Canada of Toul Meditech’s Operio Mobile and SteriStay Clean Air Zone Systems for surgery and special procedures. The ultraclean H14 filtration system creates laminar airflow at the surgical site, protec
- Arctic Vision Announces $32 Million in Series A to Expand and Develop Ophthalmology Pipelinehttps://modernod.com/news/arctic-vision-announces-32-million-in-series-a-to-expand-and-develop-ophthalmology-pipeline/2478009/Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced its $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focu
- Kodiak Sciences Announces New Longer-Term Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-new-longer-term-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-diseases/2478001/Kodiak Sciences announced promising additional safety, efficacy and durability data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet AMD, diabetic mac
- Palatin Technologies Announces Reinitiation of Enrollment of Phase 2 Study With PL9643 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-reinitiation-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2477985/Palatin Technologies announced reinitiation of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After pausing patient recruitment to ensure patient safety during the initial phases of the COVID-19 pandemic, Palatin has commenced patient recruitment in
- Santen Announces FDA Acceptance of Premarket Approval Application for DE-128 (MicroShunt) for Reviewhttps://modernod.com/news/santen-announces-fda-acceptance-of-premarket-approval-application-for-de-128-microshunt-for-review/2477976/Santen Pharmaceutical announced that the FDA has accepted the premarket approval (PMA) application for DE-128 (MicroShunt) for review. DE-128 is an investigational surgical glaucoma implant designed to reduce IOP in patients with primary open-angle glaucoma whose IOP is not controlled when using
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- Santen and NTC Announce Positive Outcome of European Decentralised Procedure (DCP) for Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-and-ntc-announce-positive-outcome-of-for-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2477944/Santen EMEA and NTC, have announced the completion and positive outcome of the European Decentralised Procedure (DCP) for a fixed dose combination of levofloxacin and dexamethasone (Ducressa), offering reduced exposure to antibiotics following cataract surgery.1 Levofloxacin is a broa